Pancreatic Cancer Research

ResearcherUniversity Hospital Schleswig-HolsteinActive in the last 2 years

Hendrik Ungefroren

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7552-2087; OpenAlex author ID A5024118927. Sources: OpenAlex.

Their work

Papers
21 (first author 1, last author 8)
Trials
0
Grants
0
Labs led
1
Collaborators
38
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: none · 2014: none · 2015: 2 papers · 2016: 2 papers · 2017: none · 2018: 2 papers · 2019: 1 paper · 2020: none · 2021: 2 papers · 2022: 1 paper · 2023: 5 papers · 2024: 1 paper · 2025: 3 papers

Papers 21

  1. Regulation of epithelial-mesenchymal plasticity in pancreatic ductal adenocarcinoma: Role of key molecules in tumor differentiation and therapy. Last author DOI 10.1016/j.ejca.2025.115561↗
  2. PDCD10/CCM3, a potential target for pancreatic ductal adenocarcinoma? Co-author DOI 10.1042/cs20241916↗
  3. Insulin-like peptide 3 is not a biomarker for pancreatic ductal adenocarcinoma. Co-author DOI 10.3389/fendo.2025.1625906↗
  4. RAC1b Collaborates with TAp73α-SMAD4 Signaling to Induce Biglycan Expression and Inhibit Basal and TGF-β-Driven Cell Motility in Human Pancreatic Cancer. Co-author DOI 10.3390/biomedicines12010199↗
  5. Molecular profiling and specific targeting of gemcitabine-resistant subclones in heterogeneous pancreatic cancer cell populations. Co-author DOI 10.3389/fonc.2023.1230382↗
  6. Elucidation of the Role of SMAD4 in Epithelial-Mesenchymal Plasticity: Does It Help to Better Understand the Consequences of DPC4 Inactivation in the Malignant… Co-author DOI 10.3390/cancers15030581↗
  7. Preclinical Patient-Derived Culture Models for Personalized Treatment of Pancreatic Cancer: A Dream of the Future or Useful Practice? First author DOI 10.3390/cancers15113027↗
  8. TAp73 Inhibits EMT and Cell Migration in Pancreatic Cancer Cells through Promoting SMAD4 Expression and SMAD4-Dependent Inhibition of ERK Activation. Co-author DOI 10.3390/cancers15153791↗
  9. Establishment and Molecular Characterization of Two Patient-Derived Pancreatic Ductal Adenocarcinoma Cell Lines as Preclinical Models for Treatment Response. Last author DOI 10.3390/cells12040587↗
  10. Suppressive Role of ACVR1/ALK2 in Basal and TGFβ1-Induced Cell Migration in Pancreatic Ductal Adenocarcinoma Cells and Identification of a Self-Perpetuating Au… Co-author DOI 10.3390/biomedicines10102640↗
  11. A Comparative Endocrine Trans-Differentiation Approach to Pancreatic Ductal Adenocarcinoma Cells with Different EMT Phenotypes Identifies Quasi-Mesenchymal Tum… Last author DOI 10.3390/cancers13184663↗
  12. Activation of a Ductal-to-Endocrine Transdifferentiation Transcriptional Program in the Pancreatic Cancer Cell Line PANC-1 Is Controlled by RAC1 and RAC1b thro… Last author DOI 10.3390/cancers13215541↗
  13. Negative Control of Cell Migration by Rac1b in Highly Metastatic Pancreatic Cancer Cells Is Mediated by Sequential Induction of Nonactivated Smad3 and Biglycan. Last author DOI 10.3390/cancers11121959↗
  14. Diabetes as risk factor for pancreatic cancer: Hyperglycemia promotes epithelial-mesenchymal-transition and stem cell properties in pancreatic ductal epithelia… Co-author DOI 10.1016/j.canlet.2017.12.004↗
  15. Downregulation of TRAIL-Receptor 1 Increases TGFβ Type II Receptor Expression and TGFβ Signalling Via MicroRNA-370-3p in Pancreatic Cancer Cells. Co-author DOI 10.3390/cancers10110399↗
  16. Proteinase-activated receptor 2 promotes TGF-β-dependent cell motility in pancreatic cancer cells by sustaining expression of the TGF-β type I receptor ALK5. Last author DOI 10.18632/oncotarget.9600↗
  17. Proteinase-Activated Receptor 2 Is a Novel Regulator of TGF-β Signaling in Pancreatic Cancer. Last author DOI 10.3390/jcm5120111↗
  18. CD4+ T cells potently induce epithelial-mesenchymal-transition in premalignant and malignant pancreatic ductal epithelial cells-novel implications of CD4+ T ce… Co-author DOI 10.1080/2162402x.2014.1000083↗
  19. Dasatinib blocks transcriptional and promigratory responses to transforming growth factor-beta in pancreatic adenocarcinoma cells through inhibition of Smad si… Last author DOI 10.1186/s12943-015-0468-0↗
  20. Characterisation of FAP-1 expression and CD95 mediated apoptosis in the A818-6 pancreatic adenocarcinoma differentiation system. Co-author DOI 10.1016/j.diff.2011.11.013↗
  21. Differential roles of Smad2 and Smad3 in the regulation of TGF-β1-mediated growth inhibition and cell migration in pancreatic ductal adenocarcinoma cells: cont… Co-author DOI 10.1186/1476-4598-10-67↗

Closest collaborators

The 25 strongest of 38 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Rüdiger Braun · 11 shared papers, 2021–2025 · strength 2.38
  2. Hendrik Lehnert · 11 shared papers, 2011–2025 · strength 1.50
  3. Ulrich Friedrich Wellner · 8 shared papers, 2021–2024 · strength 1.39
  4. Jens Uwe Marquardt · 6 shared papers, 2022–2025 · strength 1.27
  5. Tobias Keck · 3 shared papers, 2023 · strength 0.51
  6. Qi Ling · 2 shared papers, 2018–2025 · strength 0.37
  7. Richard Ivell · 1 shared paper, 2025 · strength 0.33
  8. Ravinder Anand‐Ivell · 1 shared paper, 2025 · strength 0.33
  9. Holger Kalthoff · 2 shared papers, 2012–2025 · strength 0.30
  10. Louisa Bolm · 2 shared papers, 2023 · strength 0.29
  11. Kim C. Honselmann · 2 shared papers, 2023 · strength 0.29
  12. Benedikt Färber · 2 shared papers, 2023 · strength 0.29
  13. Paula Marie Schmidtlein · 2 shared papers, 2021 · strength 0.25
  14. Hannah Otterbein · 1 shared paper, 2019 · strength 0.16
  15. H. Schäfer · 3 shared papers, 2012–2018 · strength 0.15
  16. Susanne Sebens · 3 shared papers, 2011–2018 · strength 0.15
  17. Benjamin Heckelmann · 1 shared paper, 2023 · strength 0.15
  18. Ole Helm · 2 shared papers, 2015–2018 · strength 0.12
  19. Lennart Lenk · 2 shared papers, 2015–2018 · strength 0.12
  20. Franziska Zeeh · 2 shared papers, 2016 · strength 0.11
  21. Utz Settmacher · 2 shared papers, 2016 · strength 0.11
  22. David P. Witte · 2 shared papers, 2016 · strength 0.11
  23. Anna Trauzold · 1 shared paper, 2018 · strength 0.10
  24. David I. Radke · 1 shared paper, 2018 · strength 0.10
  25. Evelin Grage‐Griebenow · 2 shared papers, 2015–2016 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.